Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Kruppel-like factor 6 (KLF6) is a tumor suppressor gene inactivated in prostate and colon cancers, as well as in astrocytic gliomas. Here, we establish that KLF6 mediates growth inhibition through an interaction with cyclin D1, leading to reduced phosphorylation of the retinoblastoma protein (Rb) at Ser795. Furthermore, introduction of KLF6 disrupts cyclin D1-cyclin-dependent kinase (cdk) 4 complexes and forces the redistribution of p21Cip/Kip onto cdk2, which promotes G1 cell cycle arrest. Our data suggest that KLF6 converges with the Rb pathway to inhibit cyclin D1/cdk4 activity, resulting in growth suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“Approximately 90% of human neoplasms have abnormalities in some component of the Rb pathway, with detectable lesions identified in either INK4a, cyclin D1, or Rb (43).”
BackgroundOuelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
The Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153 · cited 1×
“Rb phosphorylation is inactivating such that phosphorylated Rb can no longer bind its corepressor E2F, allowing transcription of growth stimulatory genes and progression of cells from G1 into S phase (35, 36).”
BackgroundCheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142 · cited 3×
“For example, the p21 family of proteins enhances cyclin D1 kinase activity at low concentrations and inhibits this activity at high concentrations (38, 39).”
BackgroundSelf-citationSpecific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 1×
“Additionally, because deregulated expression of cyclin D1 directly contributes to tumorigenesis in a number of animal model systems (16, 17), inhibition of cyclin D1 function may be an important target of cancer prevention and therapy (18).”
BackgroundAgarwal, M. L., Agarwal, A., Taylor, W. R., & Stark, G. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8493 · Cited by 858
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752 · cited 1×
“Evasion of the cyclin-dependent and the retinoblastoma (Rb) pathways are common alternative mechanisms by which tumor cells escape the G1 restriction point (13).”
BackgroundMcConnell, B. B., Gregory, F. J., Stott, F. J., Hara, E., & Peters, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1981 · Cited by 238 · cited 1×
“These findings are consistent with prior studies with keratinocytes in which p15 led to redistribution of Cip/Kip inhibitors from cdk4/6 to cdk2 (32, 33), including two independent studies demonstrating redistribution of p21 and/or p27 upon induction of p16 in U2OS cells (30, 34).”
Result
Cited by
Mammalian Krüppel-Like Factors in Health and Diseases
McConnell, B. B., & Yang, V. W. (2010) · Physiological Reviews · doi:10.1152/physrev.00058.2009 · Cited by 1,018
Ward, A. J., & Cooper, T. A. (2010) · The Journal of Pathology · doi:10.1002/path.2649 · Cited by 414
VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
ElTanbouly, M. A., Zhao, Y., Nowak, E., Li, J., Schaafsma, E., Le Mercier, I., Ceeraz, S., Lines, J. L., Peng, C., Carriere, C., et al. (2020) · Science · doi:10.1126/science.aay0524 · Cited by 292
Narla, G., Kremer-Tal, S., Matsumoto, N., Zhao, X., Yao, S., Kelley, K., Tarocchi, M., & Friedman, S. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210223 · Cited by 77
Self-citationCdk5 and the non-catalytic arrest of the neuronal cell cycle
Zhang, J., & Herrup, K. (2008) · Cell Cycle · doi:10.4161/cc.7.22.7045 · Cited by 44
Metadata
- Authors
- Benzeno, S., Narla, G., Allina, J., Cheng, G. Z., Reeves, H. L., Banck, M. S., Odin, J. A., Diehl, J. A., Germain, D., & Friedman, S. L.
- Venue
- Cancer Research
- Published
- 2004-06-01
- Volume
- 64
- Issue
- 11
- Pages
- 3885-3891
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2008543341
- Cited by
- 153
- References
- 10
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-2818
- The paper
- Benzeno, S., Narla, G., Allina, J., Cheng, G. Z., Reeves, H. L., Banck, M. S., Odin, J. A., Diehl, J. A., Germain, D., & Friedman, S. L. (2004). Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-2818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.